FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313255092> ?p ?o ?g. }

• W4313255092 endingPage "101" @default.
• W4313255092 startingPage "92" @default.
• W4313255092 abstract "Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR.Neoadjuvant lapatinib and/or trastuzumab treatment optimisation (NCT00553358) is an international, randomised, open-label, phase III study investigating the addition of lapatinib to chemotherapy plus trastuzumab in HER2-positive early BC. Ten-year event-free survival (EFS), overall survival (OS) and safety were assessed on intention-to-treat population. The association between pCR and EFS or OS was investigated in landmark population.A total of 455 patients were randomised to receive lapatinib (154), trastuzumab (149) or the combination (152). Ten-year EFS estimates were 63% (95% confidence interval [CI], 54%-71%) in the lapatinib group, 64% (95% CI, 55%-72%) in the trastuzumab group and 67% (95% CI, 58%-74%) in the combination group. Ten-year OS rates were 76% (95% CI, 67%-83%), 75% (95% CI, 66%-82%) and 80% (95% CI, 73%-86%) in the lapatinib, trastuzumab and combination groups, respectively. Women who achieved a pCR had improved EFS (hazard ratio 0.48, 95% CI, 0.31-0.73) and OS (hazard ratio 0.37, 95% CI, 0.20-0.63) compared with those who did not. The numerical difference in survival according to pCR status was greater in women treated with the combination and those with hormone-receptor-negative tumours. There were no new or long-term safety concerns.Patients with HER2-positive BC showed a durable survival benefit of neoadjuvant anti-HER2, irrespective of treatment arm. Patients who achieve pCR have significantly better outcomes than patients without pCR." @default.
• W4313255092 created "2023-01-06" @default.
• W4313255092 creator A5000708354 @default.
• W4313255092 creator A5001203491 @default.
• W4313255092 creator A5001910485 @default.
• W4313255092 creator A5003980305 @default.
• W4313255092 creator A5007286394 @default.
• W4313255092 creator A5007647646 @default.
• W4313255092 creator A5007834910 @default.
• W4313255092 creator A5017506744 @default.
• W4313255092 creator A5021122880 @default.
• W4313255092 creator A5035683674 @default.
• W4313255092 creator A5036201601 @default.
• W4313255092 creator A5040290360 @default.
• W4313255092 creator A5044222771 @default.
• W4313255092 creator A5047379707 @default.
• W4313255092 creator A5048107638 @default.
• W4313255092 creator A5053376791 @default.
• W4313255092 creator A5055292882 @default.
• W4313255092 creator A5057934302 @default.
• W4313255092 creator A5067146231 @default.
• W4313255092 creator A5067552665 @default.
• W4313255092 creator A5068100907 @default.
• W4313255092 creator A5071184343 @default.
• W4313255092 creator A5073796630 @default.
• W4313255092 creator A5081053376 @default.
• W4313255092 creator A5082195410 @default.
• W4313255092 creator A5082786838 @default.
• W4313255092 creator A5088944867 @default.
• W4313255092 date "2023-03-01" @default.
• W4313255092 modified "2023-10-01" @default.
• W4313255092 title "Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer" @default.
• W4313255092 cites W2006070721 @default.
• W4313255092 cites W2055235037 @default.
• W4313255092 cites W2075894019 @default.
• W4313255092 cites W2111578514 @default.
• W4313255092 cites W2123591186 @default.
• W4313255092 cites W2125239609 @default.
• W4313255092 cites W2155560234 @default.
• W4313255092 cites W2162982444 @default.
• W4313255092 cites W2164090407 @default.
• W4313255092 cites W2167587342 @default.
• W4313255092 cites W2175026167 @default.
• W4313255092 cites W2283816551 @default.
• W4313255092 cites W2524552969 @default.
• W4313255092 cites W2771978163 @default.
• W4313255092 cites W2965526302 @default.
• W4313255092 cites W2980885960 @default.
• W4313255092 cites W2998950563 @default.
• W4313255092 cites W3006134372 @default.
• W4313255092 cites W3093646952 @default.
• W4313255092 cites W3177344046 @default.
• W4313255092 doi "https://doi.org/10.1016/j.ejca.2022.12.020" @default.
• W4313255092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36641898" @default.
• W4313255092 hasPublicationYear "2023" @default.
• W4313255092 type Work @default.
• W4313255092 citedByCount "1" @default.
• W4313255092 countsByYear W43132550922023 @default.
• W4313255092 crossrefType "journal-article" @default.
• W4313255092 hasAuthorship W4313255092A5000708354 @default.
• W4313255092 hasAuthorship W4313255092A5001203491 @default.
• W4313255092 hasAuthorship W4313255092A5001910485 @default.
• W4313255092 hasAuthorship W4313255092A5003980305 @default.
• W4313255092 hasAuthorship W4313255092A5007286394 @default.
• W4313255092 hasAuthorship W4313255092A5007647646 @default.
• W4313255092 hasAuthorship W4313255092A5007834910 @default.
• W4313255092 hasAuthorship W4313255092A5017506744 @default.
• W4313255092 hasAuthorship W4313255092A5021122880 @default.
• W4313255092 hasAuthorship W4313255092A5035683674 @default.
• W4313255092 hasAuthorship W4313255092A5036201601 @default.
• W4313255092 hasAuthorship W4313255092A5040290360 @default.
• W4313255092 hasAuthorship W4313255092A5044222771 @default.
• W4313255092 hasAuthorship W4313255092A5047379707 @default.
• W4313255092 hasAuthorship W4313255092A5048107638 @default.
• W4313255092 hasAuthorship W4313255092A5053376791 @default.
• W4313255092 hasAuthorship W4313255092A5055292882 @default.
• W4313255092 hasAuthorship W4313255092A5057934302 @default.
• W4313255092 hasAuthorship W4313255092A5067146231 @default.
• W4313255092 hasAuthorship W4313255092A5067552665 @default.
• W4313255092 hasAuthorship W4313255092A5068100907 @default.
• W4313255092 hasAuthorship W4313255092A5071184343 @default.
• W4313255092 hasAuthorship W4313255092A5073796630 @default.
• W4313255092 hasAuthorship W4313255092A5081053376 @default.
• W4313255092 hasAuthorship W4313255092A5082195410 @default.
• W4313255092 hasAuthorship W4313255092A5082786838 @default.
• W4313255092 hasAuthorship W4313255092A5088944867 @default.
• W4313255092 hasConcept C121608353 @default.
• W4313255092 hasConcept C126322002 @default.
• W4313255092 hasConcept C143998085 @default.
• W4313255092 hasConcept C207103383 @default.
• W4313255092 hasConcept C2776694085 @default.
• W4313255092 hasConcept C2777329042 @default.
• W4313255092 hasConcept C2779786085 @default.
• W4313255092 hasConcept C2908647359 @default.
• W4313255092 hasConcept C44249647 @default.
• W4313255092 hasConcept C50382708 @default.
• W4313255092 hasConcept C530470458 @default.
• W4313255092 hasConcept C71924100 @default.

• next